Influence of Leucine Enriched Amino Acids on Myofibrillar and Collagen Protein Synthesis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

8 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-10-01

Study Completion Date

2024-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective will be to determine the effect of leucine-enriched essential amino acids (LEAA) compared to carbohydrate placebo on dietary incorporation of \[D5\] Phenylalanine \& \[D5\] Glycine into the three skeletal muscle protein pools (myofibrillar, sarcoplasmic and collagen), both following resistance exercise and at rest, with the two tracers provided as a 'intrinsically labeled' bolus. Other outcomes will relate to molecular regulation of protein synthesis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Essential and Non-Essential Amino Acids on Post-Exercise Muscle Collagen Synthesis in Young Men

NCT04596553

Skeletal Muscle Extracellular Matrix Amino Acids Metabolism +2 more

COMPLETED NA

In Vivo and in Vitro Anabolic Potential of Essential Amino Acids Following Resistance Exercise

NCT05754125

Interventional

ACTIVE_NOT_RECRUITING NA

Effect of Supplementing a Mixed Macronutrient Beverage With Graded Doses of Leucine on Myofibrillar Protein Synthesis

NCT01885429

Muscle Protein Synthesis

COMPLETED NA

Effect of Amino Acid on Muscle Damage

NCT03319147

Healthy

COMPLETED NA

Leucine Co-ingestion and Myofibrillar Protein Synthesis in Older Adults

NCT02371278

Aging Sarcopenia

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Interventional

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Crossover to receive LEAA or Carbohydrate placebo. Unilateral leg exercise to give 4 outcome. (1) LEAA-EX; (2) LEAA-REST; (3) PLACEBO-EX; (4) PLACEBO-REST

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Double blinded (investigators and participants). A lab member external to the investigation will code items for the intervention.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Leucine enriched essential amino acids

Leucine enriched essential amino acids (4g total, of which 1.6g are leucine). 20g carbohydrate, 2g of protein free drink powder, and 5g of Splenda to mask taste.

Group Type ACTIVE_COMPARATOR

Leucine enriched amino acids

Intervention Type DIETARY_SUPPLEMENT

Leucine enriched essential amino acids (4g total, of which 1.6g are leucine). 20g carbohydrate, 2g of protein free drink powder, and 5g of Splenda.

Carbohdyrate Placebo

Iso-caloric placebo (4g maltodextrin to replace LEAA). 20g carbohydrate, 2g of protein free drink powder, and 5g of Splenda to mask taste.

Group Type PLACEBO_COMPARATOR

Carbohydrate Placebo

Intervention Type DIETARY_SUPPLEMENT

iso-caloric placebo (4g maltodextrin). 20g carbohydrate, 2g of protein free drink powder, and 5g of Splenda.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Leucine enriched amino acids

Leucine enriched essential amino acids (4g total, of which 1.6g are leucine). 20g carbohydrate, 2g of protein free drink powder, and 5g of Splenda.

Intervention Type DIETARY_SUPPLEMENT

Carbohydrate Placebo

iso-caloric placebo (4g maltodextrin). 20g carbohydrate, 2g of protein free drink powder, and 5g of Splenda.

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

LEAA

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy, male and female, recreationally-active participants.
* Healthy will be defined as screened by the PAR-Q+ (The Physical Activity Readiness Questionnaire for everyone; Appendix B).
* Self-reported not having engaged in resistance exercise and/or lower body plyometrics for at least 3 months prior to the study.
* Participants will be aged 18-35 years old.
* Participants are willing to abide by the compliance rules of this study.
* Self-reported regular menstrual cycle (25-35d) within the last 3 months (female participants).

Exclusion Criteria

* Inability to adhere to any of the compliance rules judged by principle investigator or medical doctor.
* Self-reported regular tobacco use.
* Self-reported illicit drug use (e.g. growth hormone, testosterone, etc.).
* Individuals who have participated in studies within the past year involving any of the stable isotopes in the study.
* Use of birth control and discontinued use within the last 3 months (female participants).

Minimum Eligible Age

18 Years

Maximum Eligible Age

35 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes